OOIR: Observatory of International Research

Papers

(The H4-Index of Future Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	101
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	70
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	68
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	59
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	47
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	46
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	45
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	45
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	45
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	44
Sex bias phenomenon in oral cancer: an insight	44
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	43
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	42
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	39
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	39
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	39
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	38
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	37
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	34
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	34
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	33
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	32
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	32
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	32
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	31

DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	30
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	30
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	29
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	28